Skip to Main Content

Paper Details

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Blood
103
2018
Author NameAffiliation
Brian A CostelloMayo Clinic
Kilannin KrysiakDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
Kilannin KrysiakMcDonnell Genome Institute, Washington University School of Medicine
Cody A RamirezDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
Cody A RamirezMcDonnell Genome Institute, Washington University School of Medicine
Malachi GriffithDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
Malachi GriffithMcDonnell Genome Institute, Washington University School of Medicine
Obi L GriffithDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
Obi L GriffithMcDonnell Genome Institute, Washington University School of Medicine
Felicia GomezDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
Felicia GomezMcDonnell Genome Institute, Washington University School of Medicine
Todd A FehnigerDivision of Oncology and Siteman Cancer Center, Washington University School of Medicine
  • 1 - 12

Datasets